HomeCompareKNTE vs PEP

KNTE vs PEP: Dividend Comparison 2026

KNTE yields 75.47% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KNTE wins by $1.21M in total portfolio value
10 years
KNTE
KNTE
● Live price
75.47%
Share price
$2.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.35M
Annual income
$375,142.22
Full KNTE calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — KNTE vs PEP

📍 KNTE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKNTEPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KNTE + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KNTE pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KNTE
Annual income on $10K today (after 15% tax)
$6,415.09/yr
After 10yr DRIP, annual income (after tax)
$318,870.89/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, KNTE beats the other by $264,954.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KNTE + PEP for your $10,000?

KNTE: 50%PEP: 50%
100% PEP50/50100% KNTE
Portfolio after 10yr
$748.8K
Annual income
$219,286.36/yr
Blended yield
29.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

KNTE
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$30.00
+1032.1% upside vs current
Range: $30.00 — $30.00
Altman Z
1.0
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KNTE buys
0
PEP buys
0
No recent congressional trades found for KNTE or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKNTEPEP
Forward yield75.47%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$1.35M$144.7K
Annual income after 10y$375,142.22$63,430.49
Total dividends collected$1.17M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold
Analyst price target$30.00$172.43

Year-by-year: KNTE vs PEP ($10,000, DRIP)

YearKNTE PortfolioKNTE Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$18,247$7,547.17$10,854$514.44+$7.4KKNTE
2$32,395$12,870.51$11,982$758.21+$20.4KKNTE
3$56,017$21,354.74$13,526$1,136.44+$42.5KKNTE
4$94,449$34,510.84$15,727$1,741.93+$78.7KKNTE
5$155,442$54,381.15$19,012$2,750.28+$136.4KKNTE
6$249,967$83,643.80$24,173$4,514.44+$225.8KKNTE
7$393,173$125,708.24$32,789$7,793.80+$360.4KKNTE
8$605,486$184,791.09$48,258$14,354.51+$557.2KKNTE
9$913,831$265,960.98$78,586$28,686.63+$835.2KKNTE
10$1,352,941$375,142.22$144,688$63,430.49+$1.21MKNTE

KNTE vs PEP: Complete Analysis 2026

KNTEStock

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Full KNTE Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this KNTE vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KNTE vs SCHDKNTE vs JEPIKNTE vs OKNTE vs KOKNTE vs MAINKNTE vs MOKNTE vs PMKNTE vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.